Sareum Holdings PLC
RYH0
Company Profile
Business description
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
Contact
Langford Arch, London Road
Unit 2a, Pampisford
CambridgeCambridgeshireCB22 3FX
GBRT: +44 1223497700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
5
Stocks News & Analysis
stocks
CBA earnings: Business lending powers on, but costs and credit bear watching
Our view after the bank reports first quarter earnings.
stocks
Apple earnings review: Revenue beats estimates as memory crunch threatens margins
Apple shares are trading at record highs after posting solid results.
stocks
Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil
We’re reducing our long-term revenue estimates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,214.20 | 60.00 | -0.65% |
| CAC 40 | 8,361.36 | 28.49 | 0.34% |
| DAX 40 | 26,771.88 | 109.11 | 0.41% |
| Dow JONES (US) | 52,297.09 | 189.40 | -0.36% |
| FTSE 100 | 10,863.09 | 27.62 | 0.25% |
| HKSE | 23,873.18 | 135.37 | -0.56% |
| NASDAQ | 25,366.09 | 100.10 | -0.39% |
| Nikkei 225 | 61,834.84 | 1,015.48 | 1.67% |
| NZX 50 Index | 14,161.90 | 97.33 | -0.68% |
| S&P 500 | 7,592.40 | 26.98 | -0.35% |
| S&P/ASX 200 | 9,090.00 | 56.80 | -0.62% |
| SSE Composite Index | 3,664.32 | 8.49 | 0.23% |